File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Plasminogen activator inhibitor-1 and HbA1c defined prediabetes: The Guangzhou Biobank Cohort Study-CVD
  • Basic View
  • Metadata View
  • XML View
TitlePlasminogen activator inhibitor-1 and HbA1c defined prediabetes: The Guangzhou Biobank Cohort Study-CVD
 
AuthorsXu, L1 3
Jiang, CQ3
Lam, TH1
Bao, B3
Cheng, KK2
Thomas, GN2
 
Issue Date2011
 
PublisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664
 
CitationClinical Endocrinology, 2011, v. 74 n. 4, p. 528-531 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1365-2265.2010.03948.x
 
AbstractObjective To examine the association between plasminogen activator inhibitor-1 (PAI-1) and diabetes status. Research Design and Methods One thousand three hundred and ninety-three older Chinese were randomly selected from the Guangzhou Biobank Cohort Study. Diabetes status was classified as impaired HbA1c (IA1c) level of 5·7-6·4%, impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or diabetes using the American Diabetes Association diagnosis criteria in 2010. Results Compared to the normoglycemic (NG) group, 421 subjects with IA1c, but without diabetes, IFG or IGT, had adverse levels of vascular risk factors, including PAI-1, lipid profile, blood pressure and anthropometry. After adjusting for multiple potential confounders, compared to the NG group, the level of plasma PAI-1 was independently and significantly increased in the IA1c and the IFG/IGT group (mean difference: 32·0 (95% confidence interval: 5·5-58·6) ng/ml and 33·3 (6·3-60·3) ng/ml, respectively; P < 0·01). Conclusions Plasma PAI-1 level was increased in people with haemoglobin A1c (HbA1c) of 5·7-6·4% but without IFG or IGT, and in people with IFG/IGT, suggesting an increased risk for future diabetes and cardiovascular diseases in these groups. © 2011 Blackwell Publishing Ltd.
 
ISSN0300-0664
2013 Impact Factor: 3.353
 
DOIhttp://dx.doi.org/10.1111/j.1365-2265.2010.03948.x
 
ISI Accession Number IDWOS:000288073300018
Funding AgencyGrant Number
National Natural Science Foundation of China/Research Grants Council30518001
HKU720/05
University of Hong Kong Foundation for Education and Science, Hong Kong
Guangzhou Public Health Bureau
Guangzhou Science and Technology Committee, Guangzhou, China
University of Birmingham, UK
Funding Information:

The study is funded by the National Natural Science Foundation of China/Research Grants Council (No. 30518001; HKU720/05) grant. The main cohort study was funded by The University of Hong Kong Foundation for Education and Science, Hong Kong; Guangzhou Public Health Bureau, and Guangzhou Science and Technology Committee, Guangzhou, China; and The University of Birmingham, UK.

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorXu, L
 
dc.contributor.authorJiang, CQ
 
dc.contributor.authorLam, TH
 
dc.contributor.authorBao, B
 
dc.contributor.authorCheng, KK
 
dc.contributor.authorThomas, GN
 
dc.date.accessioned2011-05-11T08:32:21Z
 
dc.date.available2011-05-11T08:32:21Z
 
dc.date.issued2011
 
dc.description.abstractObjective To examine the association between plasminogen activator inhibitor-1 (PAI-1) and diabetes status. Research Design and Methods One thousand three hundred and ninety-three older Chinese were randomly selected from the Guangzhou Biobank Cohort Study. Diabetes status was classified as impaired HbA1c (IA1c) level of 5·7-6·4%, impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or diabetes using the American Diabetes Association diagnosis criteria in 2010. Results Compared to the normoglycemic (NG) group, 421 subjects with IA1c, but without diabetes, IFG or IGT, had adverse levels of vascular risk factors, including PAI-1, lipid profile, blood pressure and anthropometry. After adjusting for multiple potential confounders, compared to the NG group, the level of plasma PAI-1 was independently and significantly increased in the IA1c and the IFG/IGT group (mean difference: 32·0 (95% confidence interval: 5·5-58·6) ng/ml and 33·3 (6·3-60·3) ng/ml, respectively; P < 0·01). Conclusions Plasma PAI-1 level was increased in people with haemoglobin A1c (HbA1c) of 5·7-6·4% but without IFG or IGT, and in people with IFG/IGT, suggesting an increased risk for future diabetes and cardiovascular diseases in these groups. © 2011 Blackwell Publishing Ltd.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationClinical Endocrinology, 2011, v. 74 n. 4, p. 528-531 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1365-2265.2010.03948.x
 
dc.identifier.citeulike9000220
 
dc.identifier.doihttp://dx.doi.org/10.1111/j.1365-2265.2010.03948.x
 
dc.identifier.epage531
 
dc.identifier.hkuros184991
 
dc.identifier.isiWOS:000288073300018
Funding AgencyGrant Number
National Natural Science Foundation of China/Research Grants Council30518001
HKU720/05
University of Hong Kong Foundation for Education and Science, Hong Kong
Guangzhou Public Health Bureau
Guangzhou Science and Technology Committee, Guangzhou, China
University of Birmingham, UK
Funding Information:

The study is funded by the National Natural Science Foundation of China/Research Grants Council (No. 30518001; HKU720/05) grant. The main cohort study was funded by The University of Hong Kong Foundation for Education and Science, Hong Kong; Guangzhou Public Health Bureau, and Guangzhou Science and Technology Committee, Guangzhou, China; and The University of Birmingham, UK.

 
dc.identifier.issn0300-0664
2013 Impact Factor: 3.353
 
dc.identifier.issue4
 
dc.identifier.openurl
 
dc.identifier.pmid21128994
 
dc.identifier.scopuseid_2-s2.0-79952437473
 
dc.identifier.spage528
 
dc.identifier.urihttp://hdl.handle.net/10722/133339
 
dc.identifier.volume74
 
dc.languageeng
 
dc.publisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofClinical Endocrinology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsThe definitive version is available at www.blackwell-synergy.com
 
dc.titlePlasminogen activator inhibitor-1 and HbA1c defined prediabetes: The Guangzhou Biobank Cohort Study-CVD
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Xu, L</contributor.author>
<contributor.author>Jiang, CQ</contributor.author>
<contributor.author>Lam, TH</contributor.author>
<contributor.author>Bao, B</contributor.author>
<contributor.author>Cheng, KK</contributor.author>
<contributor.author>Thomas, GN</contributor.author>
<date.accessioned>2011-05-11T08:32:21Z</date.accessioned>
<date.available>2011-05-11T08:32:21Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Clinical Endocrinology, 2011, v. 74 n. 4, p. 528-531</identifier.citation>
<identifier.issn>0300-0664</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/133339</identifier.uri>
<description.abstract>Objective To examine the association between plasminogen activator inhibitor-1 (PAI-1) and diabetes status. Research Design and Methods One thousand three hundred and ninety-three older Chinese were randomly selected from the Guangzhou Biobank Cohort Study. Diabetes status was classified as impaired HbA1c (IA1c) level of 5&#183;7-6&#183;4%, impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or diabetes using the American Diabetes Association diagnosis criteria in 2010. Results Compared to the normoglycemic (NG) group, 421 subjects with IA1c, but without diabetes, IFG or IGT, had adverse levels of vascular risk factors, including PAI-1, lipid profile, blood pressure and anthropometry. After adjusting for multiple potential confounders, compared to the NG group, the level of plasma PAI-1 was independently and significantly increased in the IA1c and the IFG/IGT group (mean difference: 32&#183;0 (95% confidence interval: 5&#183;5-58&#183;6) ng/ml and 33&#183;3 (6&#183;3-60&#183;3) ng/ml, respectively; P &lt; 0&#183;01). Conclusions Plasma PAI-1 level was increased in people with haemoglobin A1c (HbA1c) of 5&#183;7-6&#183;4% but without IFG or IGT, and in people with IFG/IGT, suggesting an increased risk for future diabetes and cardiovascular diseases in these groups. &#169; 2011 Blackwell Publishing Ltd.</description.abstract>
<language>eng</language>
<publisher>Wiley-Blackwell Publishing Ltd.. The Journal&apos;s web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664</publisher>
<relation.ispartof>Clinical Endocrinology</relation.ispartof>
<rights>The definitive version is available at www.blackwell-synergy.com</rights>
<title>Plasminogen activator inhibitor-1 and HbA1c defined prediabetes: The Guangzhou Biobank Cohort Study-CVD</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0300-0664&amp;volume=74&amp;issue=4&amp;spage=528&amp;epage=531&amp;date=2011&amp;atitle=Plasminogen+activator+inhibitor-1+and+HbA1c+defined+prediabetes:+The+Guangzhou+Biobank+Cohort+Study-CVD</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1111/j.1365-2265.2010.03948.x</identifier.doi>
<identifier.pmid>21128994</identifier.pmid>
<identifier.scopus>eid_2-s2.0-79952437473</identifier.scopus>
<identifier.hkuros>184991</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-79952437473&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>74</identifier.volume>
<identifier.issue>4</identifier.issue>
<identifier.spage>528</identifier.spage>
<identifier.epage>531</identifier.epage>
<identifier.isi>WOS:000288073300018</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<identifier.citeulike>9000220</identifier.citeulike>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. University of Birmingham
  3. Guangzhou No. 12 Hospital